Economy

U.S. Launches Regulatory Reforms and Proposed Tariffs to Boost Domestic Drug Manufacturing

Illustration for: U.S. Launches Regulatory Reforms and Proposed Tariffs to Boost Domestic Drug Manufacturing
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

Jul 23, 2026

THE BARE STORY

The U.S. government is enacting regulatory changes and tariff proposals aimed at moving pharmaceutical manufacturing to the United States. Generic medications currently account for approximately 90 percent of all U.S. prescriptions, but much of their production remains outside the country.

To address this, the Food and Drug Administration (FDA) launched the PreCheck Pilot Program under an executive order signed by President Donald Trump. Acting FDA Commissioner Kyle Diamantas stated that more than 70 percent of primary manufacturing facilities supplying U.S. prescriptions are currently located overseas. According to Diamantas, the pilot program aims to accelerate domestic production by offering early technical feedback and fast-tracking inspections for participating companies. The Department of Health and Human Services (HHS) also introduced an initiative called "Operation TrialBlazer" to relocate clinical trials to the United States.

In addition to regulatory reforms, President Trump announced plans to levy a 100 percent tariff on imported generic drugs beginning in August 2028, with the tax rising to 200 percent the following year. White House spokesman Kush Desai stated that the policy provides a two-year transition window for businesses, supported by measures such as equipment expensing.

The tariff proposal has drawn skepticism from health policy experts. Marta Wosińska of the Brookings Institution and Mariana Socal of Johns Hopkins University noted that the high cost of building specialized domestic facilities could lead some manufacturers to abandon the U.S. market entirely, potentially causing drug shortages or raising consumer prices. Additionally, Sandoz CEO Richard Saynor called for a more collaborative framework between industry leaders and policymakers to address the transition.

Same Facts. Different Perspectives.

Two AI models. Two viewpoints. One factual foundation.

Right Perspective

• Incentivizing Domestic Production Imposing 100 to 200 percent tariffs creates a powerful, clear economic signal that redirects private capital back into domestic manufacturing. Forcing companies to internalize the systemic risks of foreign supply lines is the most effective way to build long-term market resilience and production capacity. When combined with tax incentives like equipment expensing, this policy successfully drives tangible capital investment in high-value American infrastructure.

• Accelerating Regulatory Efficiency Streamlining bureaucratic obstacles through the FDA PreCheck Pilot and Operation TrialBlazer restores market efficiency to the pharmaceutical sector. Fast-tracking inspections and providing early technical feedback reduces costly regulatory friction, allowing domestic producers to scale operations and bring clinical trials home. Cutting this administrative red tape empowers American enterprises to expand and operate without being choked by state-level inertia.

• Securing Long-Term Sovereignty Addressing the reality that over 70 percent of primary manufacturing facilities are located overseas is a fundamental requirement for systemic economic stability. Relying on foreign nations for 90 percent of critical prescriptions exposes the domestic economy to extreme strategic vulnerability. While transition friction may occur, the two-year policy runway ensures a controlled market realignment that ultimately protects the nation's economic and health sovereignty.

How it may affect me

As a U.S. reader:

• You may experience higher out-of-pocket costs for generic medications, which make up 90 percent of prescriptions, when proposed import tariffs of 100 to 200 percent take effect in 2028 and 2029.

• You could face potential drug shortages if the high cost of building domestic facilities drives foreign manufacturers to abandon the U.S. market.

• You may see faster development and domestic availability of new treatments as clinical trials relocate to the United States and the FDA fast-tracks inspections.

• You could benefit from a more reliable long-term supply of daily medications as the U.S. reduces its strategic reliance on the overseas facilities that currently produce over 70 percent of primary prescriptions.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.